267 related articles for article (PubMed ID: 11089877)
1. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma.
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Nesland JM; Berner A; Bryne M; Reich R
Clin Exp Metastasis; 1999; 17(10):799-808. PubMed ID: 11089877
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma.
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Nesland JM; Reich R
Mol Cell Endocrinol; 2002 Feb; 187(1-2):39-45. PubMed ID: 11988310
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
4. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels.
Davidson B; Reich R; Berner A; Givant-Horwitz V; Goldberg I; Risberg B; Kristensen GB; Trope CG; Bryne M; Kopolovic J; Nesland JM
Eur J Cancer; 2001 Nov; 37(16):2040-9. PubMed ID: 11597382
[TBL] [Abstract][Full Text] [Related]
5. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization.
Davidson B; Goldberg I; Kopolovic J; Lerner-Geva L; Gotlieb WH; Ben-Baruch G; Reich R
Gynecol Oncol; 1999 Jun; 73(3):372-82. PubMed ID: 10366463
[TBL] [Abstract][Full Text] [Related]
6. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study.
Davidson B; Gotlieb WH; Ben-Baruch G; Kopolovic J; Goldberg I; Nesland JM; Berner A; Bjåmer A; Bryne M
Gynecol Oncol; 2000 Apr; 77(1):35-43. PubMed ID: 10739688
[TBL] [Abstract][Full Text] [Related]
7. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.
Davidson B; Reich R; Goldberg I; Gotlieb WH; Kopolovic J; Berner A; Ben-Baruch G; Bryne M; Nesland JM
Clin Cancer Res; 2001 Mar; 7(3):551-7. PubMed ID: 11297247
[TBL] [Abstract][Full Text] [Related]
8. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
[TBL] [Abstract][Full Text] [Related]
9. Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Risberg B; Ben-Baruch G; Reich R
Cancer Metastasis Rev; 2003 Mar; 22(1):103-15. PubMed ID: 12716042
[TBL] [Abstract][Full Text] [Related]
10. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma.
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Reich R
Clin Cancer Res; 2003 Apr; 9(4):1412-9. PubMed ID: 12684413
[TBL] [Abstract][Full Text] [Related]
11. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
12. Expression and localization of matrix metalloproteinases (MT1-MMP, MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) during synepitheliochorial placentation of goats (Capra hircus).
Uekita T; Yamanouchi K; Sato H; Tojo H; Seiki M; Tachi C
Placenta; 2004 Nov; 25(10):810-9. PubMed ID: 15451196
[TBL] [Abstract][Full Text] [Related]
13. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts.
Afzal S; Lalani EN; Poulsom R; Stubbs A; Rowlinson G; Sato H; Seiki M; Stamp GW
Hum Pathol; 1998 Feb; 29(2):155-65. PubMed ID: 9490275
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
Schwandner O; Schlamp A; Broll R; Bruch HP
Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
[TBL] [Abstract][Full Text] [Related]
15. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
16. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Am J Clin Pathol; 2000 Sep; 114(3):402-11. PubMed ID: 10989641
[TBL] [Abstract][Full Text] [Related]
17. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
19. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.
Jones JL; Glynn P; Walker RA
J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569
[TBL] [Abstract][Full Text] [Related]
20. [Correlation between MMP-2 activation and MT1-MMP mRNA expression in thymic epithelial tumors].
Wang Y; Ueda Y; Shimasaki M; Liu N; Wang EH
Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):18-23. PubMed ID: 16608644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
